By Paras P. Vakharia, MD, PharmD, as told to Keri Wiginton
Vakharia is assistant professor of dermatology at Northwestern University Feinberg School of Medicine in Chicago. The information here represents his knowledge and clinical experience. Vakharia has expertise in medical and pharmacy training. He was not involved in the development of icotrokinra (Icotyde).
If you or someone you love has psoriasis, you know it’s more than dry or irritated skin. Psoriasis can cause itching, soreness, and painful cracks in the skin. In some cases, those cracks can bleed. It can show up almost anywhere, but common spots include elbows, knees, scalp, hands, feet, and lower back.
What’s often underestimated, especially by people who don’t live with the condition, is how much psoriasis can spill into the rest of your life. Symptoms can disrupt sleep, make work harder, strain relationships, and wear on your mental health.
Because psoriasis is a long-term condition, treatment focuses on keeping symptoms in check and helping you feel more like yourself day to day. We now have far more effective choices than in the past.
One of the newer options being studied is a pill called icotrokinra (Icotyde). It’s getting attention because it could offer strong results in a simpler form for people with moderate-to-severe plaque psoriasis. Here’s what to know about how it works and what to ask your doctor.
Who is this treatment for?
Icotrokinra has been studied in adults and kids ages 12 and older with moderate-to-severe plaque psoriasis. If you hear “moderate to severe” and aren’t sure whether it fits you, that’s very common. Doctors have clear ways to sort that out.
When you meet with a dermatologist, they’ll look at more than just your skin in the exam room. They’ll consider how much of your body is affected and where your psoriasis shows up.
If you have more than a few palm-sized patches, your psoriasis likely goes beyond mild. And even smaller areas can be a big problem if they’re on places like the scalp, hands, feet, groin, or nails, which tend to be harder to treat and more disruptive.
How psoriasis affects your daily life matters just as much. If symptoms make it hard to sleep, work, feel comfortable around other people, or feel good about yourself, that’s an important part of the decision too.
What’s different about this drug?
The biggest difference is that icotrokinra is a pill that targets the same immune pathway as some of the most effective psoriasis treatments used today. Those medications work well but are given as shots. This is the first oral drug designed to offer that same targeted approach.
Older psoriasis pills work in a more general way, either by dampening the immune system overall or by affecting inflammation less precisely.
Icotrokinra works by blocking a part of your immune system called interleukin-23. IL-23 plays a major role in psoriasis by driving inflammation that leads to thick, scaly plaques. When that signal is turned down, skin symptoms can improve.
One way to think about it is this: IL-23 acts like a key that turns inflammation on. The receptor is the lock. Icotrokinra blocks the lock, so the key can’t turn and start the process. What’s new is that this level of targeting is happening in a pill, which hasn’t been easy to achieve.
Compared with older oral psoriasis treatments, icotrokinra appears to be much more effective with fewer tradeoffs. Earlier pills often didn’t clear skin very well and could cause side effects like upset stomach, mood changes, broader immune effects, or the need for frequent blood tests.
Based on current studies, this medication seems to avoid many of those issues while offering stronger results for the skin.
How effective is this treatment? How fast does it work?
No treatment works the same for everyone, but results so far have been encouraging. In clinical trials, many people started to see visible improvement by about three months. By three to four months, about half of people taking icotrokinra had at least 90% of their psoriasis cleared.
That’s a strong result for a pill. Injectable treatments still tend to have the highest skin-clearing rates overall, but icotrokinra comes close. And the improvement didn’t stop early. In studies, many people continued to see their skin get better the longer they stayed on treatment.
In real life, it’s reasonable to give the medication at least three months to see whether it’s helping you. If you’re seeing meaningful improvement by then, you can stay on it. If not, you and your doctor can talk through other options and decide what makes the most sense next.
How do you take it?
You take it by mouth as a pill. In studies, people took the medication and then waited about 30 minutes before eating. There’s no special handling required.
For many people, that simpler routine might make treatment easier to stick with, especially if you want an effective medicine but don’t like needles.
Are there any side effects? How do you manage them?
Most people in clinical trials did well with icotrokinra. The most common side effects were mild upper respiratory infections, such as cold-like symptoms. Some people also had mild stomach upset or headaches, which usually got better as their bodies got used to the medication.
Because icotrokinra affects part of your immune system, it’s still important to take basic safety steps. Staying up-to-date on vaccines and being mindful around people who are sick can help lower your risk of infections. If you notice that you’re getting sick more often than usual, let your doctor know.
Overall, the risks look similar to what doctors already see with injectable IL-23 medications, without sore spots from shots.
Is this treatment safe?
Based on what we know so far, yes. Icotrokinra’s safety profile appears better than older oral psoriasis medications and similar to injectable IL-23 biologics.
One key difference is what you don’t need to do. You don’t need routine blood tests, and the medication doesn’t weaken your whole immune system. That makes it easier to use and lowers some of the risks you see with older treatments.
How long do you take it?
Psoriasis is a chronic condition, which means it doesn’t go away for good. Treatments like icotrokinra are meant for long-term use. If you stop taking it, symptoms will likely come back.
That doesn’t mean you can never take a break, but you should always talk to your doctor before stopping. This isn’t a medicine you take only during flares. It’s meant to help keep your psoriasis under control over time.
How often will you need follow-ups?
You’ll usually check in with your dermatologist about three months after starting treatment to see how you’re doing and make sure you’re tolerating it well. If things are going smoothly, visits can be spaced out. You may only need yearly follow-ups once your psoriasis is stable.
This is similar to how doctors manage injectable medicines.
Will insurance cover it?
Coverage will depend on your insurance plan once the drug is approved. In general, pills tend to cost less than injections, but icotrokinra is still a complex medication and likely won’t be cheap.
Some insurance plans may ask you to try other treatments first. Your dermatologist can help by working with your insurance company and explaining why a specific medication is right for you.
How can you find out if icotrokinra is right for you?
The first step is a conversation with your dermatologist. Share how psoriasis affects your life, not just how it looks. If you don’t want injections, say that. If psoriasis interferes with your sleep, work, or mental health, make sure that’s also part of the discussion.
Treatment decisions work best when they’re made together, based on your health needs and what matters most to you.
How carefully was this drug studied?
Icotrokinra has been tested in large, well-designed studies. Researchers kept close track of how well it worked and how safe it was. The data is strong and seems to apply broadly to people with psoriasis. Doctors feel confident that the results show real improvement in psoriasis treatment.
For many people with plaque psoriasis, icotrokinra offers a new option — a targeted pill that fits between creams and shots. Even if it’s not right for everyone, it shows how far psoriasis care has come and gives you another choice when deciding how to manage your condition.
While research will continue to track long-term outcomes, the results so far suggest this medication could fill an important gap in treatment.
Related Links 
